Vaxgen - HIV/Aids weltweit einzigartig - 500 Beiträge pro Seite

[Deka1]

Beschäftige mich schon seit 3 Monaten mit Vaxgen und bin
ebensolange investiert.
Die sind in der Erforschung eines Aidsimpfstoffes der
Konkurrenz wirklich um 3-5 Jahre voraus.
Der entwickelte Imfpstoff wird zur Zeit an etwa 5500 Test-
personen in Thailand und an etwa 2500 Personen in
Afrika getestet.
Ergebnisse will Vaxgen Anfang 2001 verkünden.
Ist das Ergebnis positiv, gibt es nach oben kein Grenzen.

Charttechnich sieht Vaxgen ebenfalls einwandfrei aus.
Nach Ausbruch über 26 $ zum ATH bei 34$ und zurück bis
27 $.

Gebe aber nicht viel auf die Charttechnik bei Vaxgen
und bleibe einige Jahre investiert.
Habe bei 32 Euro noch mal langfristig nachgelegt.
Vorsicht: noch kaum Umsätze in BRD, daher streng limitieren.
Euer
Deka1

[chini]

Hallo Deka1
Freut mich,daß sich außer mir noch jemand mit Vaxgen beschäftigt.
Allerdings möchte ich Deine Ausführungen etws korrigieren.
In Thailand werden 2500 Personen und in Amerika und Europa
5400 Personen getestet.
Und Ergebnisse werden nicht Anfang sondern Ende 2001 bekanntgegeben.
Trotzdem ist Vaxgen der absolute Knaller.
Und bis Ende 2001 wird sicherlich noch viel durchsickern.
Jede noch so kleine Meldung hat der Aktie jedesmal einen Schub
versetzt.
Gruss
chini

[Guru-Schreck]

Tuesday May 29, 9:00 am Eastern Time

Press Release

SOURCE: VaxGen, Inc.

VaxGen AIDS Vaccine May Produce Broader Immunity Than Previously Detected

BRISBANE, Calif., May 29 /PRNewswire/ -- VaxGen, Inc. (Nasdaq: VXGN - news) presented laboratory data last week at a scientific conference indicating that the company`s
HIV/AIDS vaccine induces immune responses capable of preventing infection from a broader array of HIV strains than previously detected. The finding represents new evidence that the
vaccine, AIDSVAX, may be effective against HIV strains found in nature, also known as primary isolates, or ``wild type`` strains.
(Photo: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGO )

The finding was made possible by a new assay developed at VaxGen that allowed company scientists to more accurately measure how well antibodies induced by the vaccine,
AIDSVAX, prevented cell-to-cell transmission of the virus. Cell-to-cell transmission, in which a diseased human cell infects healthy ones, is considered one of the major routes of
spreading HIV infection.

The new assay showed that antibodies induced by the vaccine bound to the infected immune cells, known as T cells. Furthermore, the antibodies prevented the diseased cells from
infecting healthy ones in four out of five experiments, each of which used a different primary isolate strain. The assay also showed that prevention of infection increased as the level of
antibodies increased.

The data were presented last week at the Cold Spring Harbor 2001 Meeting on Retroviruses. Paul A. Escarpe, a VaxGen virologist, was the lead author of the work, with co-authorship
from four other company scientists.

``These are preliminary laboratory results that need additional confirmation, but they are encouraging because they indicate that AIDSVAX induces the type of antibodies necessary to
prevent HIV infection in real-life settings,`` said Donald P. Francis, M.D., D.Sc., VaxGen`s president. ``Additionally, if our Phase III trials demonstrate that AIDSVAX is effective, we
believe this assay will be an important tool to help us more rapidly develop vaccines for additional geographic areas.``

VaxGen is the only company with preventive HIV vaccines in Phase III trials, the final stage before regulatory approval can be sought. The company is conducting two trials, one in North
America and Europe and another in Thailand, with 7,900 volunteers. The trials are designed to determine how well AIDSVAX prevents HIV infection. Results from the trial in North
America and Europe, which is nine months ahead of the Thai trial, are expected either in November 2001 or 12 months thereafter. VaxGen is located in Brisbane, Calif. For more
information, please visit the company`s web site at www.vaxgen.com.

NOTE: AIDSVAX® is a registered trademark of VaxGen.

Note: This news release contains ``forward-looking statements`` within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject
to known and unknown risks, uncertainties or other factors that may cause VaxGen`s actual results to be materially different from historical results, expressed or implied by such
forward-looking statements. Factors that might cause such a difference include, but are not limited to, uncertainties related to the progress, costs and results of the Company`s Phase III
clinical trials, the progress of other internal research and development projects, the establishment of collaborative arrangements with governmental agencies, the receipt of research grants
and the timing of certain expenses. If VaxGen is able to demonstrate efficacy of AIDSVAX in clinical trials, VaxGen may not be able to obtain regulatory clearance to market
AIDSVAX. The findings in the new assay may not be relevant for determining the protective effect of AIDSVAX against HIV and may not help VaxGen develop current or planned
formulations for preventive vaccines. Reference should be made to VaxGen`s Annual Report on Form 10-K, filed with the Securities and Exchange Commission, for a more detailed
description of such factors discussed in the ``Factors Affecting Future Results`` and ``Business`` sections. Readers are cautioned not to place undue reliance on these forward-looking
statements that speak only as of the date of this release. VaxGen undertakes no obligation to update publicly any forward- looking statements to reflect new information, events, or
circumstances after the date of this release or to reflect the occurrence of anticipated events.

SOURCE: VaxGen, Inc.

[Guru-Schreck]

Some Early Good News on AIDS Vaccine Sends VaxGen
Soaring
By Adam Feuerstein
Staff Reporter
5/29/01 7:13 PM ET


Shares in VaxGen (VXGN:Nasdaq - news) jumped more than 26% Tuesday
after the biotech firm said its experimental HIV/AIDS vaccine may produce a
broader immunity than previously thought.

But while VaxGen has pushed its vaccine, known as Aidsvax, further down
the development pipeline than any of its rivals, approval of any HIV/AIDS
vaccine is still a long shot, observers say.

Tuesday, the Brisbane, Calif., company said it presented data at a scientific
conference last week indicating that Aidsvax induced immune responses
capable of preventing infection from a broad array of HIV strains, including HIV
strains found in nature, or "wild type" strains of the disease.

"These are preliminary laboratory results that need additional confirmation, but
they are encouraging because they indicate that Aidsvax induces the type of
antibodies necessary to prevent HIV infection in real-life settings," said Donald
Francis, VaxGen`s president, in a statement.

Investors jumped all over the news, pushing shares in VaxGen up $5, or
26.4%, to $23.89 in Tuesday trading.

VaxGen is in the middle of two pivotal, late-stage tests of its vaccine. Interim
results from the tests will be unveiled in November, and if positive, they could
form the basis for a marketing application to the Food and Drug
Administration.

The discovery of an effective HIV/AIDS vaccine is one of modern medicine`s
great quests. More than 36 million people are infected with the HIV virus
worldwide, according to the World Health Organization. Last year, 2.5
million adults and 500,000 children died from diseases related to AIDS, while
4.7 million adults and 600,000 children became infected with HIV.

But searching for a HIV/AIDS vaccine -- and actually finding one that works --
are two different issues, making this a risky area for investors, says John
McCamant, editor of the Medical Technology Stock Letter.

"I`ve covered HIV since the late 1980s so I understand the tremendous need
for a safe and effective vaccine, but this is one area where I think investors
should stay away. There`s too much roulette involved here," he says.
McCamant doesn`t have a position in VaxGen.

The problem, he says, is developing a vaccine that is truly effective. In
VaxGen`s case, the FDA says it will consider approval if the vaccine is
effective in at least 30% of patients. While VaxGen`s development efforts are
furthest along, McCamant believes that rival treatments may prove to be more
effective.

"You need pioneers like VaxGen to open the door, but I just don`t think it`s a
place where investors should be putting their money," he says, adding that
the best way for investors to place a safer bet on VaxGen would be to invest
in Genentech (DNA:NYSE - news), which spun out the company in 1995 and
now owns 11%.

Other companies pursuing an HIV/AIDS vaccine include GlaxoSmithKline
(GSK:NYSE - news), Chiron (CHIR:Nasdaq - news), Immune Response
(IMNR:Nasdaq - news) and Merck (MRK:NYSE - news). Last week,
GlaxoSmithKline announced positive results from its efforts, although the
experimental vaccines are still being tested in the laboratory and have not yet
been tried on patients.

Lance Ignon, a VaxGen spokesman, says the company is pushing for an
Aidsvax efficacy rate higher than the minimum 30% standard set by the FDA.
But even at those levels, a first-generation vaccine would be a success.

"It`s a common misperception that vaccines are 100% effective. In reality, very
few new vaccines are 100% effective," he says. "Vaccines routinely go
through improvements and changes that boost their effectiveness, and
Aidsvax, if approved, will be no different."

For instance, a HIV/AIDS vaccine, even one that is partially effective, could
play a huge role in reducing the number of new infections in areas like Africa,
where HIV and AIDS run rampant.

VaxGen`s decision to release positive findings Tuesday paid off nicely for at
least one group of institutional investors. On May 24, the Halifax Fund,
managed by the Palladin Group, led a group of investors who sunk $20
million into VaxGen through a private placement of convertible stock. The
20,000 shares of preferred stock are convertible into an undisclosed amount of
VaxGen common stock at $23.22 a share.

Ignon says investors in the private placement had no inside knowledge of
when the scientific findings were going to be released.

"We presented our findings at the scientific conference last Thursday," he
says. "We wanted to get the news out because it was material information,
but we wanted to do it in a very conservative way. These investors had
absolutely no idea that we were going to release this information."

[4now]

hallo sind uebrigens seit mitte des monats im nasdaq biotech index
,...
uebrigens visible genetics ist in einem aehnlichen bereich und erwartet ergebnisse im july VGIN

[Guru-Schreck]

Tuesday June 26, 9:15 am Eastern Time

Press Release

SOURCE: VaxGen, Inc.

VaxGen`s AIDS Vaccine for Developing World Shows Unexpected Activity

Results May Yield Vaccine With Broader Protection

BRISBANE, Calif., June 26 /PRNewswire/ -- VaxGen, Inc. (Nasdaq: VXGN - news) presented laboratory data today at an
international scientific conference indicating that antibodies to HIV subtype C (HIV-C) have an unexpected ability to bind to
significant regions of another HIV subtype. The findings indicate that a vaccine that induces HIV-C antibodies may be effective
at preventing infection not only by HIV-C but by other subtypes as well. HIV-C causes half of the world`s HIV infections and
is the predominant subtype in southern Africa, India and China.
(Photo: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGO )

VaxGen also described a new trivalent formulation of its vaccine, AIDSVAX, which is designed to prevent infection by three
of the world`s five major HIV subtypes, including HIV-C. The development of this formulation, which has yet to be tested in
human clinical trials, furthers the company`s goal of tailoring vaccines to target specific HIV subtypes and strains in various
geographic regions.

``We found that antibodies to HIV-C bind well to a functionally significant site on the C subtype and to the same site on the B
subtype,`` said Phillip Berman, Ph.D., VaxGen`s senior vice president of research and development. ``In contrast, antibodies to
HIV-B did not bind nearly as well to the same region on HIV-C. These findings are from animal studies and need to be
confirmed in humans, but they suggest that a vaccine directed against HIV-C may be able to protect against a broader range of
different HIV subtypes than other vaccine formulations.``

The functionally significant site, known as the V3 loop, is a critical feature of HIV because it is one of several keys that unlock
the door to human cells and allow the virus to enter and replicate. If antibodies bind to the loop effectively enough, the infection
process should be halted.

Dr. Berman presented these findings today at the sixth European Conference on Experimental AIDS Research (ECEAR) in
Edinburgh, Scotland. Dr. Berman was the lead author of the findings; other VaxGen scientists co-authored the study.

Dr. Berman also described how VaxGen has developed its first trivalent vaccine by combining antigens from the B, C and E
HIV subtypes. ``These findings are encouraging because they further demonstrate that it is possible to mix envelope proteins
from different strains of viruses to create multivalent vaccines that may be effective against a variety of HIV subtypes,`` Dr.
Berman said.

VaxGen is developing vaccines that induce antibodies that bind to the surface of HIV with the goal of preventing the virus from entering human cells. If HIV can`t
enter human cells, it dies off in the bloodstream and cannot cause AIDS. Antibodies are the only immunologic response known to prevent HIV infection in
animals, including chimpanzees, which are thought to be the source of the virus.

VaxGen is the only company with preventive HIV vaccines in Phase III trials, the final stage before regulatory approval can be sought. VaxGen is conducting two
trials, one in North America and Europe and another in Thailand, with a total of 7,900 volunteers. The trials are designed to determine how well AIDSVAX
prevents HIV infection. VaxGen was co-founded by Donald P. Francis, M.D., D.Sc., and Robert Nowinski, Ph.D. Dr. Francis leads the development of the
vaccine, and Dr. Nowinski, who retired last year, was the company`s entrepreneur, financing the company at its origin and key early stages. Dr. Berman invented
AIDSVAX. VaxGen is located in Brisbane, Calif. For more information, please visit the company`s web site at www.vaxgen.com.

NOTE: AIDSVAX® is a registered trademark of VaxGen.

Note: This news release contains ``forward-looking statements`` within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking
statements are subject to known and unknown risks, uncertainties or other factors that may cause VaxGen`s actual results to be materially different from historical
results, expressed or implied by such forward-looking statements. Factors that might cause such a difference include, but are not limited to, uncertainties related
to the progress, costs and results of the Company`s Phase III clinical trials, the progress of other internal research and development projects, the establishment of
collaborative arrangements with governmental agencies, the receipt of research grants and the timing of certain expenses. Even if VaxGen is able to demonstrate
efficacy of AIDSVAX in clinical trials, VaxGen may not be able to obtain regulatory clearance to market AIDSVAX. The findings reported in this press release
may not be relevant for determining the protective effect of AIDSVAX against HIV, may not help VaxGen develop current or planned formulations for
preventive vaccines and may not be repeatable in human trials. Reference should be made to VaxGen`s Annual Report on Form 10-K, filed with the Securities
and Exchange Commission, for a more detailed description of such factors discussed in the ``Factors Affecting Future Results`` and ``Business`` sections. Readers
are cautioned not to place undue reliance on these forward-looking statements which speak only as of the date of this release. VaxGen undertakes no obligation
to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release or to reflect the occurrence of
anticipated events.

SOURCE: VaxGen, Inc.

[Guru-Schreck]

Neueste Meldung von finance online
Mittwoch, 27.06.2001, 11:35

VaxGen mit positiven Testresultaten bei HIV-Mittel

Die VaxGen Inc. veröffentlichte Labordaten, wonach Antikörper
gegen HIV der Nebenart C (HIV-C) auch gegen andere HIV
Nebenarten wirksam sind. Damit könnte ein Impfstoff, der
Antikörper bildet auch eine Infektion mit anderen HIV Nebenarten
verhindern.

HIV-C ist die überwiegend auftretende HIV Nebenart in Indien,
China und im südlichen Afrika. Die Hälfte der weltweiten HIV-Infektionen beruht auf der Nebenart HIV-C.

Weiterhin befindet sich eine dreiwertige Version seines Impfstoffs AIDSVAX in klinischen Tests am Menschen. Mit diesem
Medikament kann die Infektion von drei der fünf bedeutetsten Nebenarten verhindert werden, darunter auch HIV-C.

VaxGen entwickelt Impfstoffe, die Antikörper bilden. Diese verbinden sich mit der Oberfläche des HIV und verhindern so das
Eindringen des Virus in die menschlichen Zellen. Kann das Virus nicht in eine menschliche Zelle gelangen, so stirbt es und
kann kein AIDS verursachen. Es ist das einzige Unternehmen, welches vorbeugende HIV Impfstoffe in Phase III Tests führt.
Dies ist die letzte Stufe, bevor die Marktzulassung beantragt werden kann.

Die Aktien stiegen an der Nasdaq um 4,68 Prozent auf einen Schlusskurs von 20,13 Dollar.